CPSE:ALK BPharmaceuticals
Assessing ALK-Abelló (CPSE:ALK B) Valuation After CHMP Backing For Expanded EURneffy Use In Children
ALK-Abelló (CPSE:ALK B) is back in focus after regulators in Europe issued a positive opinion on extending EURneffy marketing authorisation to include a 1 mg nasal adrenaline spray for younger children.
See our latest analysis for ALK-Abelló.
The CHMP opinion appears to have been a fresh catalyst, with ALK-Abelló’s 1-day share price return of 2.12% standing out against a 30-day share price return decline of 6.44%. Its 1-year total shareholder return of 34.35% and 3-year total shareholder...